AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON AUGUST 7, 2002.
REGISTRATION NO. 333-88358
================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
----------------
AMENDMENT NO. 1
TO
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
----------------
WEST PHARMACEUTICAL SERVICES, INC.
(Exact name of Registrant as specified in its charter)
PENNSYLVANIA 3060 23-1210010
(State or Other Jurisdiction (Primary Standard Industrial (I.R.S. Employer
of Incorporation or Organization) Classification Code Number) Identification No.)
----------------
101 GORDON DRIVE
LIONVILLE, PA 19341
(610) 594-2900
(Address, Including Zip Code, and Telephone Number, Including Area Code,
of Registrant's Principal Executive Offices)
----------------
JOHN R. GAILEY III, ESQ.
VICE PRESIDENT, GENERAL COUNSEL AND SECRETARY
WEST PHARMACEUTICAL SERVICES, INC.
101 GORDON DRIVE
LIONVILLE, PA 19341
(610) 594-2900
(Name, address including zip code, and telephone number, including area code,
of agent for service)
----------------
With Copies to:
CHRISTOPHER G. KARRAS, ESQ.
DECHERT
4000 BELL ATLANTIC TOWER
1717 ARCH STREET
PHILADELPHIA, PA 19103
(215) 994-4000
----------------
APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: From time
to time after the effective date of this Registration Statement.
If the only securities being registered on this Form are being offered
pursuant to dividend or interest reinvestment plans, please check the following
box. [ ]
If any of the securities being registered on this Form are to be offered on
a delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, other than securities offered only in connection with dividend or interest
reinvestment plans, check the following box. [X]
If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. [ ]
If this Form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [ ]
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. [ ]
----------------
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES
AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE
A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT
SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(A) OF THE
SECURITIES ACT OF 1933 OR UNTIL THIS REGISTRATION STATEMENT SHALL BECOME
EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(A),
MAY DETERMINE.
================================================================================
The information in this prospectus is not complete and may be changed. The
securities described in this prospectus may not be sold until the registration
statement filed with the Securities and Exchange Commission is effective. This
prospectus is not an offer to sell these securities and is not soliciting an
offer to buy these securities in any state where the offer or sale is not
permitted.
SUBJECT TO COMPLETION, DATED AUGUST 7, 2002
PROSPECTUS
40,000 SHARES
[WEST PHARMACEUTICAL LOGO OMITTED]
WEST PHARMACEUTICAL SERVICES, INC.
COMMON STOCK
This prospectus relates to up to 40,000 shares of our common stock that may
be offered for sale by The Herman O. West Foundation, or its donees, pledgees,
transferees, assignees or other successors-in-interest, as described more fully
in this prospectus under the heading "Selling Shareholder" on page 3. The shares
of our common stock covered by this prospectus are shares that we may donate to
the Foundation from time to time over the next three years.
We will not receive any proceeds from the sale of shares of our common
stock by the Foundation. We are paying the expenses of this offering.
The primary market for our common stock is the New York Stock Exchange,
where it trades under the symbol "WST". On August 6, 2002, the last reported
sale price of our common stock on the New York Stock Exchange was $25.42 per
share.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS
PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A
CRIMINAL OFFENSE.
The date of this Prospectus is , 2002
TABLE OF CONTENTS
Where You Can Find More Information............................................1
Incorporation by Reference.....................................................2
Cautionary Statement Concerning Forward-Looking Statements.....................2
Use of Proceeds................................................................3
Selling Shareholder............................................................3
Plan of Distribution...........................................................4
Legal Matters..................................................................5
Experts........................................................................5
Transfer Agent.................................................................5
WHERE YOU CAN FIND MORE INFORMATION
Because we are subject to the informational requirements of the Securities
Exchange Act of 1934, as amended, we file annual, quarterly and current reports,
proxy statements and other information with the Securities and Exchange
Commission. You may read and copy these reports, proxy statements and other
information at the public reference facilities maintained by the SEC at Room
1024, 450 Fifth Street, N.W., Washington, D.C. 20549. You also may obtain copies
of these materials at prescribed rates from the public reference section of the
SEC at 450 Fifth Street, Washington, D.C. 20549. You may obtain information on
the operation of the public reference room by calling the SEC at (800) SEC-0330.
In addition, we are required to file electronic versions of these materials with
the SEC through the SEC's EDGAR system. The SEC maintains a web site at
http://www.sec.gov that contains reports, proxy and information statements and
other information regarding registrants that file electronically with the SEC.
We have filed with the SEC a registration statement on Form S-3 under the
Securities Act with respect to the securities offered under this prospectus.
This prospectus does not contain all of the information in the registration
statement, parts of which we have omitted, as allowed under the rules and
regulations of the SEC. You should refer to the registration statement for
further information with respect to us and our securities. Statements contained
in this prospectus as to the contents of any contract or other document are not
necessarily complete and, in each instance, we refer you to the copy of each
contract or document filed as an exhibit to the registration statement. Copies
of the registration statement, including exhibits, may be inspected without
charge at the SEC's principal office in Washington, D.C., and you may obtain
copies from this office upon payment of the fees prescribed by the SEC.
We will furnish without charge to each person to whom a copy of this
prospectus is delivered, upon written or oral request, a copy of any and all of
these filings and any information incorporated by reference in this prospectus
(except exhibits, unless they are specifically incorporated by reference into
this prospectus). You should direct any requests for copies to:
West Pharmaceutical Services, Inc.
101 Gordon Drive
Lionville, PA 19341
Attention: John R. Gailey III, Esq.
(610) 594-2900
WE HAVE AUTHORIZED NO ONE TO GIVE YOU ANY INFORMATION OR TO MAKE ANY
REPRESENTATION ABOUT US OR THE SECURITIES OFFERED BY THIS PROSPECTUS THAT
DIFFERS FROM OR ADDS TO THE INFORMATION CONTAINED IN THIS PROSPECTUS OR IN THE
DOCUMENTS WE HAVE FILED PUBLICLY WITH THE SEC. THEREFORE, IF ANYONE SHOULD GIVE
YOU ANY DIFFERENT OR ADDITIONAL INFORMATION, YOU SHOULD NOT RELY ON IT.
IF YOU LIVE IN A JURISDICTION WHERE IT IS UNLAWFUL TO OFFER TO SELL, OR TO
ASK FOR OFFERS TO BUY, THE SECURITIES OFFERED BY THIS PROSPECTUS, OR, IF YOU ARE
A PERSON TO WHOM IT IS UNLAWFUL TO DIRECT SUCH ACTIVITIES, THEN THE OFFER
PRESENTED BY THIS PROSPECTUS DOES NOT EXTEND TO YOU.
THE INFORMATION CONTAINED IN THIS PROSPECTUS SPEAKS ONLY AS OF THE DATE
INDICATED ON THE COVER OF THIS PROSPECTUS UNLESS THE INFORMATION SPECIFICALLY
INDICATES THAT ANOTHER DATE APPLIES.
INCORPORATION BY REFERENCE
The SEC allows us to incorporate by reference the information we file with
it, which means that we can disclose important information to you by referring
you to those documents. We have incorporated by reference into this prospectus
the following documents or information filed with the SEC (Commission File No.
1-8036):
Annual Report on Form 10-K For the Fiscal year ended December 31, 2001
Quarterly Report on Form 10-Q For the Fiscal Quarter ended March 31, 2002
Current Report of Form 8-K Filed on May 1, 2002
Description of our common stock set forth Filed on October 17, 1980
in our Registration Statement on Form 8-A
You may obtain copies of these documents from us, free of cost, by
contacting us at the address or telephone number provided in "Where You Can Find
More Information" on page 1.
Information that we file with the SEC after the date of this prospectus but
prior to the termination of this offering, including documents filed pursuant to
Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, shall be deemed
incorporated by reference into this prospectus and will automatically update and
supersede information contained in this prospectus. You will be deemed to have
notice of all information incorporated by reference in this prospectus as if
that information was included in this prospectus.
CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
This prospectus contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. The words "estimate",
"expect", "intend", "believe" and similar expressions are intended to identify
forward-looking statements. These forward-looking statements involve known and
unknown risks and uncertainties. Many factors could cause our actual results,
performance or achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by such
forward-looking statements, including but not limited to:
o sales demand;
o the timing and success of customers' projects;
o competitive pressures;
o the strength or weakness of the U.S. dollar;
o inflation;
o the cost of raw materials;
o continued cost-improvement programs;
o statutory tax rates; and
o significant asset dispositions.
We do not intend to update these forward-looking statements.
2
USE OF PROCEEDS
All of the shares of our common stock offered by this prospectus will be
sold by the Foundation. As a result, we will not receive any of the proceeds
from the sale of these shares.
SELLING SHAREHOLDER
Our board of directors has approved the donation of up to 40,000 shares of
our common stock to the Foundation. The donation of these shares may occur from
time to time over the next three years. The Foundation may use this prospectus
to sell from time to time some or all of the shares that we donate to them.
The Foundation was created in 1972 and is recognized by the Internal
Revenue Service as a private foundation described in section 501(c)(3) of the
Internal Revenue Code. The Foundation:
o provides college scholarships to children and other dependents of our
U.S. full-time employees;
o provides financial assistance to nonprofit organizations serving the
cultural, health and public service needs of the communities where we
maintain operations; and
o encourages financial support of education by matching (within certain
limits) the contributions of our full-time employees, retirees and
directors to eligible educational institutions.
The address for the Foundation is The Herman O. West Foundation, c/o West
Pharmaceuticals, Inc., 101 Gordon Drive, Lionville, PA 19341.
The following table sets forth, as of the date of this prospectus, the
maximum number of donated shares of our common stock that the Foundation may
sell using this prospectus. To the best of our knowledge, the Foundation does
not own more than one percent of our outstanding shares of common stock either
before or after the sales contemplated by this prospectus.
Number of Shares Covered
Name by This Prospectus
---- -------------------------
The Herman O. West Foundation (1)................. 40,000(2)
---------------
(1) Although no formal relationship exists between us and the Foundation, we
make annual contributions to the Foundation. George R. Bennyhoff, a former
executive of the company, and William G. Little, a current senior executive
officer of our company, are trustees of the Foundation. Dr. Franklin H.
West, who is not an affiliate of our company, exercises sole voting and
dispositive power over these shares of common stock.
(2) Represents 40,000 shares of our common stock which we may donate to the
Foundation from time to time over the next three years. However, we are
under no legal obligation to issue, and the Foundation has no legal
entitlement to receive, these shares.
Future sales of our common stock may, if required, be accompanied by a
supplement to this prospectus setting forth the name of the selling shareholder
using that prospectus supplement, the number of shares being sold and a
supplemental plan of distribution describing the specific manner of sale of
those shares.
3
PLAN OF DISTRIBUTION
The Foundation, and its donees, pledgees, transferees, assignees and other
successors-in-interest, may offer and sell, from time to time, some or all of
the shares of common stock covered by this prospectus. Although we are under no
legal obligation to donate all or any portion of the 40,000 shares covered by
this prospectus, we have registered the offer and sale of these shares so that,
if we donate some or all of them, these shares may be freely sold to the public
by the Foundation. Registration of the shares of our common stock covered by
this prospectus does not mean, however, that we necessarily will donate all or
any portion of the shares to the Foundation or that, if donated, these shares
will be offered or sold by the Foundation. We will not receive any proceeds from
the sale of the shares covered by this prospectus. See "Use of Proceeds". We
will pay all costs, expenses and fees in connection with the registration of the
shares of common stock, including fees of our counsel and accountants, fees
payable to the SEC and listing fees. We estimate those fees and expenses to be
approximately $37,000. The Foundation will pay all underwriting discounts and
commissions and similar selling expenses, if any, attributable to the sale of
the shares of common stock covered by this prospectus.
The Foundation (including its donees, pledgees, transferees, assignees or
other successors-in-interest who, after the date of this prospectus, receive
from the Foundation any portion of the shares covered by this prospectus
pursuant to a gift, pledge or other transaction not involving a sale) may sell
the shares described in this prospectus from time to time, at market prices
prevailing at the time of sale, at prices related to market prices, at a fixed
price or at prices subject to change or at negotiated prices, by a variety of
methods including:
o in privately negotiated transactions;
o through broker-dealers, who may act as agents or principals;
o in a block trade in which a broker-dealer will attempt to sell a block
of shares of common stock as agent but may position and resell a
portion of the block as principal to facilitate the transaction;
o through one or more underwriters on a firm commitment or best-efforts
basis;
o directly to one or more purchasers;
o through agents;
o in the over-the-counter market;
o through put or call options transactions relating to shares of our
common stock;
o to cover short sales of our common stock; or
o in any combination of the above.
The broker-dealers through or to whom the shares of our common stock may be
sold may be deemed underwriters of the shares within the meaning of the
Securities Act of 1933, as amended, in which event all brokerage commissions or
discounts and other compensation received by those broker-dealers may be deemed
to be underwriting compensation. To the extent required, the names of any
underwriters and applicable commissions or discounts and any other required
information with respect to any particular sale will be set forth in an
accompanying prospectus supplement.
The Foundation has advised us that as of the date of this prospectus it has
not entered into any agreements, understandings or arrangements with any
underwriters or broker-dealers regarding the sale of the shares covered by this
prospectus, nor is there an underwriter or coordinating broker acting in
connection with the proposed sale of shares by the Foundation. However, if the
Foundation subsequently enters into any of these types of arrangements,
broker-dealers engaged by the Foundation may arrange for other broker-dealers to
participate. Broker-dealer transactions may include:
o purchases of the shares of common stock by a broker-dealer as
principal and resales of the shares of common stock by the
broker-dealer for its account pursuant to this prospectus;
o ordinary brokerage transactions; or
o transactions in which the broker-dealer solicits purchasers.
4
In connection with the sale of the shares of common stock covered by this
prospectus through underwriters, underwriters may receive compensation in the
form of underwriting discounts or commissions and also may receive commissions
from purchasers of shares of common stock for whom they may act as agent.
Underwriters may sell to or through broker-dealers, and such broker-dealers may
receive compensation in the form of discounts, concessions or commissions from
the underwriters and/or commissions from the purchasers for whom they may act as
agent. The discounts and commissions described in this paragraph may exceed
those customary in the types of transactions involved.
At the time a particular offer of the shares of common stock covered by
this prospectus is made, a revised prospectus or prospectus supplement, if
required, will be distributed, which will set forth the aggregate amount of
shares of common stock covered by this prospectus being offered and the terms of
the offering, including the name or names of any underwriters, dealers, brokers
or agents, any discounts, commissions, concessions and other items constituting
compensation from the selling shareholders and any discounts, commissions or
concessions allowed or reallowed or paid to dealers. Such revised prospectus or
prospectus supplement, and, if necessary, a post-effective amendment to the
registration statement of which this prospectus is a part, will be filed with
the SEC to reflect the disclosure of additional information with respect to the
distribution of the shares of common stock covered by this prospectus. In
addition, if the Foundation notifies us that one or more of its donees,
pledgees, transferees, assignees or other successors-in-interest intends to sell
more than 500 shares, a supplement to this prospectus will be filed.
Because the Foundation may be deemed an "underwriter" within the meaning of
Section 2(11) of the Securities Act, the Foundation will be subject to the
prospectus delivery requirements of the Securities Act. We have informed the
Foundation that the anti-manipulative provisions of Regulation M promulgated
under the Exchange Act, may apply to its sales in the market.
The Foundation may sell the shares of common stock covered by this
prospectus pursuant to Rule 144 promulgated under the Securities Act, rather
than pursuant to this prospectus.
LEGAL MATTERS
The validity of the shares of our common stock offered by this prospectus
will be passed upon for us by John R. Gailey III. Mr. Gailey is one of our
full-time employees, holding the title of Vice President, General Counsel and
Secretary. As of April 30, 2002, Mr. Gailey beneficially owned 10,343 shares of
our common stock and had options to acquire an additional 24,000 shares of our
common stock.
EXPERTS
The financial statements incorporated in this prospectus by reference to
our Annual Report on Form 10-K for the year ended December 31, 2001, have been
so incorporated in reliance on the report of PricewaterhouseCoopers LLP,
independent accountants, given on the authority of said firm as experts in
auditing and accounting.
TRANSFER AGENT
American Stock Transfer and Trust Company, Inc. serves as the transfer
agent for our common stock.
5
40,000 SHARES
[WEST PHARMACEUTICAL LOGO OMITTED]
WEST PHARMACEUTICAL SERVICES, INC.
COMMON STOCK
----------
PROSPECTUS
----------
, 2002
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION
The estimated expenses to be paid by the Registrant in connection with the
distribution of the securities being registered, other than underwriting
discounts and commissions, are as follows:
SEC Registration Fee................................................. $ 107.00
Accounting Fees and Expenses......................................... 12,000.00
Blue Sky Fees and Expenses........................................... 5,000.00
Legal Fees and Expenses.............................................. 15,000.00
Printing and Engraving Expenses...................................... 2,000.00
Miscellaneous Fees and Expenses...................................... 2,893.00
----------
TOTAL........................................................... $37,000.00
==========
ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS
The Registrant maintains a policy of insurance under which the respective
directors and officers (as defined therein) of the Registrant are insured
subject to specified exclusions and deductible and retention and maximum amounts
against loss arising from any civil claim or claims which may be made against
any director or officer (as so defined) of the Registrant by reason of any
breach of duty, neglect, error, misstatement, misleading statement, omission or
act done or wrongfully attempted or alleged to have been done while acting in
their respective capacities.
Section 8 of Article II of the Bylaws of the Registrant provides that a
director shall not be personally liable for monetary damages for any action
taken on of after January 27, 1987, or for failure to take any action on or
after such date unless (i) the director has breached or failed to perform the
duties of his office under Section 8363 of the Pennsylvania Directors Liability
Act (Act 145 of 1986, P.L. 1458), relating to standard of care and justifiable
reliance, and (ii) the breach or failure to perform constitutes self-dealing,
willful misconduct or recklessness. The provisions of Section 8 of Article II of
the Bylaws shall not apply to (i) any criminal statute or (ii) the liability of
a director for the payment of taxes due to local, state or federal law.
Article IV of the Bylaws provides that the Registrant shall indemnify any
person who was or is a party or threatened to be made a party to any threatened,
pending or completed action, suit or proceeding by reason of the fact that such
person is or was a director, officer, employee or agent of the Registrant or
serving at the request of the Registrant as a director, officer, employee or
agent of another entity. Such indemnification shall be against all expenses,
judgments, fines and amounts paid in settlement of such proceedings to the
extent that such person has not otherwise been indemnified and the power to give
such indemnification has been granted by statute. For this purpose, the Board
has the power to buy and maintain insurance at the Registrant's expense. Payment
of expenses may be made to an indemnified person prior to the final disposition
of an action.
The Pennsylvania Directors Liability Act and the Pennsylvania Business
Corporations Law authorize the indemnification set forth above if the actions of
the person to be indemnified did not constitute willful misconduct or
recklessness or, in the opinion of the Registrant, self-dealing. The character
of the conduct of the person to be indemnified shall be determined by members of
the Board not parties to such litigation, independent counsel or the
shareholders of the Registrant. The obligation of the Registrant to indemnify a
director, officer, employee or agent under Article IV of the Bylaws constitutes
a contract between the Registrant and such person, and no modification or repeal
of any provision of Article IV of the Bylaws will affect, to the detriment of
the director, officer, employee or agent, such obligations of the Registrant in
connection with a claim based in any act or failure to act occurring before such
modification or repeal.
II-1
ITEM 16. EXHIBITS
Exhibit No. Description
--------------- --------------------------------------------------------------
4(a) Articles 5, 6, 8(c) and 9 of the Amended and Restated
Articles of Incorporation of the Registrant
incorporated by reference to Exhibit (3)(a) of the
Registrant's Annual Report on Form 10-K for the year
ended December 31, 1998 (File No. 1-8036).
4(b) Article I and V of the Bylaws of the Registrant, as amended,
incorporated by reference to Exhibit (3)(b) to the
Registrant's Form 10-Q for the quarter ended September 30,
1998 (File No. 1-8036).
4(c) Form of stock certificate for common stock incorporated
by reference to Exhibit (4)(a) of the Registrant's
Annual Report on Form 10-K for the year ended December
31, 1998 (File No. 1-8036).
5(a)* Opinion of John R. Gailey III, Esq.
23(a) Consent of PricewaterhouseCoopers LLP
23(b)* Consent of John R. Gailey III, Esq. (included in Exhibit 5(a)
above)
24(a)* Power of Attorney of Tenley E. Albright
24(b)* Power of Attorney of John W. Conway
24(c)* Power of Attorney of George W. Ebright
24(d)* Power of Attorney of L. Robert Johnson
24(e)* Power of Attorney of William H. Longfield
24(f)* Power of Attorney of John P. Neafsey
24(g)* Power of Attorney of Anthony Welters
24(h)* Power of Attorney of Geoffrey F. Worden
--------------------
* previously filed
ITEM 17. UNDERTAKINGS
2. The undersigned registrant hereby undertakes:
o To file, during any period in which offers or sales are being made, a
post-effective amendment to this registration statement:
o To include any prospectus required by section 10(a)(3) of the
Securities Act of 1933;
o To reflect in the prospectus any facts or events arising after
the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate,
represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of
securities offered (if the total dollar value of securities offered would not
exceed that which was registered) and any deviation from the low or high end of
the estimated maximum offering range may be reflected in the form of prospectus
filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the
changes in volume and price represent no more than 20% change in the maximum
aggregate offering price set forth in the "Calculation of Registration Fee"
table in the effective registration statement.
o To include any material information with respect to the plan of
distribution not previously disclosed in the registration statement or any
material change to such information in the registration statement;
Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of
this section do not apply if the registration statement is on
Form S-3, Form S-8 or Form F-3, and the information required to
be included in a post-effective amendment by those paragraphs is
contained in periodic reports filed with or furnished to the
Commission by the registrant pursuant to section 13 or section
15(d) of the Securities Exchange Act of 1934 that are
incorporated by reference in the registration statement.
II-2
o That, for the purpose of determining any liability under
the Securities Act of 1933, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered therein,
and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof.
o To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the termination of
the offering.
3. The undersigned registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act of 1933, each filing of the
registrant's annual report pursuant to section 13(a) or section 15(d) of the
Securities Exchange Act of 1934 (and, where applicable, each filing of an
employee benefit plan's annual report pursuant to section 15(d) of the
Securities Exchange Act of 1934) that is incorporated by reference in the
registration statement shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.
4. Insofar as indemnification for liabilities arising under the
Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise,
the registrant has been advised that in the opinion of the Securities and
Exchange Commission such indemnification is against public policy as expressed
in the Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the
registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or
proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the registrant will, unless in
the opinion of its counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in the Act and will
be governed by the final adjudication of such issue.
II-3
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant
certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-3 and has duly caused this registration
statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in Lionville, Township of Uwchlan, Commonwealth of Pennsylvania, on
August 7, 2002.
WEST PHARMACEUTICAL SERVICES, INC.
By: /s/ JOHN R. GAILEY III
-----------------------------------
John R. Gailey III
Vice President, General Counsel and
Secretary
Pursuant to the requirements of the Securities Act of 1933, this
registration statement has been signed by the following persons in the
capacities and on the dates indicated on August 7, 2002.
SIGNATURE TITLE
-------------------------------- ----------------------------------------
/s/ DONALD E. MOREL, JR. Director, President and Chief Executive
-------------------------------- Officer (principal executive officer)
Donald E. Morel, Jr.
/s/ LINDA R. ALTEMUS Vice President and Chief Financial
-------------------------------- Officer (principal financial officer)
Linda R. Altemus
/s/ JOSEPH E. ABBOTT Vice President and Corporate Controller
-------------------------------- (principal accounting officer)
Joseph E. Abbott
* Director
--------------------------------
Tenley E. Albright
* Director
--------------------------------
John W. Conway
* Director
--------------------------------
George W. Ebright
* Director
--------------------------------
L. Robert Johnson
/s/ WILLIAM G. LITTLE Director
--------------------------------
William G. Little
* Director
--------------------------------
William H. Longfield
* Director
--------------------------------
John P. Neafsey
* Director
--------------------------------
Anthony Welters
* Director
--------------------------------
Geoffrey F. Worden
*By: /s/ JOHN R. GAILEY III
---------------------------
John R. Gailey III
Attorney-in-Fact
EXHIBIT INDEX
Exhibit No. Description
-------------------- -------------------------------------------------------
4(a) Articles 5, 6, 8(c) and 9 of the Amended and Restated
Articles of Incorporation of the Registrant
incorporated by reference to Exhibit (3)(a) of the
Registrant's Annual Report on Form 10-K for the year
ended December 31, 1998 (File No. 1-8036).
4(b) Article I and V of the Bylaws of the Registrant, as
amended, incorporated by reference to Exhibit (3)(b) to
the Registrant's Form 10-Q for the quarter ended
September 30, 1998 (File No. 1-8036).
4(c) Form of stock certificate for common stock incorporated
by reference to Exhibit (4)(a) of the Registrant's
Annual Report on Form 10-K for the year ended December
31, 1998 (File No. 1-8036).
5(a)* Opinion of John R. Gailey III, Esq.
23(a) Consent of PricewaterhouseCoopers LLP
23(b)* Consent of John R. Gailey III, Esq. (included in
Exhibit 5(a) above)
24(a)* Power of Attorney of Tenley E. Albright
24(b)* Power of Attorney of John W. Conway
24(c)* Power of Attorney of George W. Ebright
24(d)* Power of Attorney of L. Robert Johnson
24(e)* Power of Attorney of William H. Longfield
24(f)* Power of Attorney of John P. Neafsey
24(g)* Power of Attorney of Anthony Welters
24(h)* Power of Attorney of Geoffrey F. Worden
--------------------
* previously filed
EXHIBIT 23(a)
CONSENT OF INDEPENDENT ACCOUNTANTS
We hereby consent to the incorporation by reference in this Registration
Statement on Form S-3 of our report dated February 28, 2002 relating to the
financial statements, which appears in the 2001 Annual Report to Shareholders,
which is incorporated by reference in West Pharmaceutical Services, Inc.'s
Annual Report on Form 10-K for the year ended December 31, 2001. We also consent
to the references to us under the heading "Experts" in such registration
statement.
/s/ PRICEWATERHOUSECOOPERS LLP
PricewaterhouseCoopers LLP
Philadelphia, PA
August 7, 2002